{"id":2269,"date":"2025-12-12T11:49:28","date_gmt":"2025-12-12T03:49:28","guid":{"rendered":"https:\/\/www.jhm-biopharma.com\/en_US\/?p=2269"},"modified":"2025-12-29T14:53:53","modified_gmt":"2025-12-29T06:53:53","slug":"jhm-biopharmaceutical-begins-clinical-trial-of-its-recombinant-type-a-botulinum-toxin-for-stroke-related-spasticity-2","status":"publish","type":"post","link":"https:\/\/www.jhm-biopharma.com\/en_US\/news\/p2269\/","title":{"rendered":"JHM Biopharmaceutical has initiated the Phase III trial for recombinant botulinum neurotoxin of type A in treating upper limb spasticity in adults, with enrollment of the first patient completed."},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"2269\" class=\"elementor elementor-2269\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5a15a571 e-con-full e-flex e-con e-parent\" data-id=\"5a15a571\" data-element_type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-70cad45a e-con-full e-flex e-con e-child\" data-id=\"70cad45a\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-83fac4e elementor-widget elementor-widget-theme-post-title elementor-page-title elementor-widget-heading\" data-id=\"83fac4e\" data-element_type=\"widget\" data-widget_type=\"theme-post-title.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">JHM Biopharmaceutical has initiated the Phase III trial for recombinant botulinum neurotoxin of type A in treating upper limb spasticity in adults, with enrollment of the first patient completed.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7cdae306 elementor-widget elementor-widget-post-info\" data-id=\"7cdae306\" data-element_type=\"widget\" data-widget_type=\"post-info.default\">\n\t\t\t\t\t\t\t<ul class=\"elementor-inline-items elementor-icon-list-items elementor-post-info\">\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item elementor-repeater-item-d26a18c elementor-inline-item\" itemprop=\"datePublished\">\n\t\t\t\t\t\t<a href=\"https:\/\/www.jhm-biopharma.com\/en_US\/date\/2025\/12\/12\/\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-calendar-alt\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M0 464c0 26.5 21.5 48 48 48h352c26.5 0 48-21.5 48-48V192H0v272zm320-196c0-6.6 5.4-12 12-12h40c6.6 0 12 5.4 12 12v40c0 6.6-5.4 12-12 12h-40c-6.6 0-12-5.4-12-12v-40zm0 128c0-6.6 5.4-12 12-12h40c6.6 0 12 5.4 12 12v40c0 6.6-5.4 12-12 12h-40c-6.6 0-12-5.4-12-12v-40zM192 268c0-6.6 5.4-12 12-12h40c6.6 0 12 5.4 12 12v40c0 6.6-5.4 12-12 12h-40c-6.6 0-12-5.4-12-12v-40zm0 128c0-6.6 5.4-12 12-12h40c6.6 0 12 5.4 12 12v40c0 6.6-5.4 12-12 12h-40c-6.6 0-12-5.4-12-12v-40zM64 268c0-6.6 5.4-12 12-12h40c6.6 0 12 5.4 12 12v40c0 6.6-5.4 12-12 12H76c-6.6 0-12-5.4-12-12v-40zm0 128c0-6.6 5.4-12 12-12h40c6.6 0 12 5.4 12 12v40c0 6.6-5.4 12-12 12H76c-6.6 0-12-5.4-12-12v-40zM400 64h-48V16c0-8.8-7.2-16-16-16h-32c-8.8 0-16 7.2-16 16v48H160V16c0-8.8-7.2-16-16-16h-32c-8.8 0-16 7.2-16 16v48H48C21.5 64 0 85.5 0 112v48h448v-48c0-26.5-21.5-48-48-48z\"><\/path><\/svg>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text elementor-post-info__item elementor-post-info__item--type-date\">\n\t\t\t\t\t\t\t\t\t\t<time>2025-12-12<\/time>\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t<\/li>\n\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1748acb6 elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"1748acb6\" data-element_type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c84d72c elementor-widget elementor-widget-text-editor\" data-id=\"c84d72c\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Today, <strong>JHM Biopharmaceutical (Hangzhou) Co., Ltd.<\/strong> (hereinafter referred to as \u201cJHM BIOPHARMA\u201d) announce key progress in its independently developed injectable recombinant botulinum neurotoxin of type A. This product, manufactured and applied by its wholly-owned subsidiary JHM Biopharmaceutical (Tonghua) Co., Ltd., is intended for upper limb spasticity after stroke in adults. Its Phase III clinical trial has been approved by the National Medical Products Administration. This clinical trial-jointly led by Professor Fang Li, from Huashan Hospital of Fudan University, and Professor JingLing Jin, from Yangzhi Affiliated Rehabilitation Hospital of Tongji University (also known as Shanghai Sunshine Rehabilitation Center)-has officially commenced and completed the enrollment of the world&#8217;s first patient in the Phase III clinical trial of recombinant botulinum neurotoxin of type A for this indication, bringing a new breakthrough to this therapeutic area.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4843c866 e-con-full e-flex e-con e-child\" data-id=\"4843c866\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-36a856c elementor-widget elementor-widget-image\" data-id=\"36a856c\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"800\" height=\"492\" src=\"https:\/\/www.jhm-biopharma.com\/en_US\/wp-content\/uploads\/sites\/5\/2025\/12\/Weixin-Image_20251211155306_5_38-1024x630.jpg\" class=\"attachment-large size-large wp-image-2261\" alt=\"\" srcset=\"https:\/\/www.jhm-biopharma.com\/en_US\/wp-content\/uploads\/sites\/5\/2025\/12\/Weixin-Image_20251211155306_5_38-1024x630.jpg 1024w, https:\/\/www.jhm-biopharma.com\/en_US\/wp-content\/uploads\/sites\/5\/2025\/12\/Weixin-Image_20251211155306_5_38-300x185.jpg 300w, https:\/\/www.jhm-biopharma.com\/en_US\/wp-content\/uploads\/sites\/5\/2025\/12\/Weixin-Image_20251211155306_5_38-768x473.jpg 768w, https:\/\/www.jhm-biopharma.com\/en_US\/wp-content\/uploads\/sites\/5\/2025\/12\/Weixin-Image_20251211155306_5_38.jpg 1300w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dab15e8 elementor-widget elementor-widget-text-editor\" data-id=\"dab15e8\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><em>Figure: The Initiate Meeting of the First Phase III Clinical Research Center for Upper Limb Spasticity after Stroke in Adults<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-20c343e elementor-widget elementor-widget-text-editor\" data-id=\"20c343e\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><strong>Dr. Chunsheng Leng, the Founder and Chief Scientist of JHM BIOPHARMA, stated<\/strong>\uff1a\u201cWe are highly confident that we can steadily advance the trial progress according to the research plan, to achieve the clinical transformation potential of this product as soon as possible, so that more patients can bendfit from high-quality and innovative biological treatment solutions.\u201d<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-266825a e-con-full e-flex e-con e-child\" data-id=\"266825a\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b0baf52 elementor-widget elementor-widget-image\" data-id=\"b0baf52\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"800\" height=\"759\" src=\"https:\/\/www.jhm-biopharma.com\/en_US\/wp-content\/uploads\/sites\/5\/2025\/12\/Weixin-Image_20251211155021_4_38-1024x971.jpg\" class=\"attachment-large size-large wp-image-2260\" alt=\"\" srcset=\"https:\/\/www.jhm-biopharma.com\/en_US\/wp-content\/uploads\/sites\/5\/2025\/12\/Weixin-Image_20251211155021_4_38-1024x971.jpg 1024w, https:\/\/www.jhm-biopharma.com\/en_US\/wp-content\/uploads\/sites\/5\/2025\/12\/Weixin-Image_20251211155021_4_38-300x285.jpg 300w, https:\/\/www.jhm-biopharma.com\/en_US\/wp-content\/uploads\/sites\/5\/2025\/12\/Weixin-Image_20251211155021_4_38-768x728.jpg 768w, https:\/\/www.jhm-biopharma.com\/en_US\/wp-content\/uploads\/sites\/5\/2025\/12\/Weixin-Image_20251211155021_4_38.jpg 1300w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cec500a elementor-widget elementor-widget-text-editor\" data-id=\"cec500a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><em>Figure: Professor Jin Lingjing, from Shanghai Yangzhi Rehabilitation Hospital, is administering the injection to the first participant.<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7eede00 elementor-widget elementor-widget-text-editor\" data-id=\"7eede00\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>This recombinant botulinum neurotoxin of type A was developed using genetic engineering, protein engineering and structural biology technologies, breaking through key technical barriers such as recombinant expression and formulation processes. It not only eliminates\u00a0the biosafety risks in traditional preparation methods, but also demonstrates significant advantages in purity, activity and safety. It is expected to become an upgraded alternative to existing traditional botulinum toxin products.<\/p><p>As one of the first enterprises pioneering to master the core technology of recombinant botulinum neurotoxin of type A, the advancement of the Phase III clinical trial by JHM BIOPHARMA has not only established a critical foundation for its commercialization, but also poised to reshape the competitive landscape of the botulinum toxin market, promoting industry-wide advancements in safer, more controllable, and more efficient product development.<\/p><p>-The End-<\/p><p><strong>About <\/strong><strong>JHM Biopharmaceutical (Hangzhou) Co., Ltd.<\/strong><\/p><p>JHM BIOPHARMA is an enterprise dedicated to the development and commercialization of innovative synthetic biology products and technologies. JHM is committed to advancing the use of innovative recombinant protein drugs in endocrine therapy, neurotherapy, and other next-generation biomedical material applications. Our mission is to provide groundbreaking biopharmaceutical products and treatments to patients worldwide. JHM BIOPHARMA portfolio includes\u00a0recombinant botulinum neurotoxin of type A, human growth hormone injection, long-acting recombinant human growth hormone, single layer artificial dermis repair material (recombinant fully human), bilayer artificial dermis repair material(recombinant fully human), scaffold for cartilage repair(recombinant fully human).<\/p><p>Headquartered in Hangzhou, Zhejiang Province, JHM BIOPHARMA has established GMP-compliant manufacturing facilities in both Hangzhou and Tonghua. The enterprise possesses integrated capabilities spanning early drug discovery, process development, clinical research, manufacturing, and commercialization, giving it a competitive edge in driving rapid industry advancement and innovation. Since its inception, JHM BIOPHARMA has completed multiple rounds of financing, reflecting strong recognition from the capital markets regarding the enterprise&#8217;s technological expertise, product pipeline, and commercial potential. In 2024, the enterprise was designated as a \u201cSpecialized and Sophisticated SME in Zhejiang Province.\u201d\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a90a911 elementor-post-navigation-borders-yes elementor-widget elementor-widget-post-navigation\" data-id=\"a90a911\" data-element_type=\"widget\" data-widget_type=\"post-navigation.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-post-navigation\" role=\"navigation\" aria-label=\"Post Navigation\">\n\t\t\t<div class=\"elementor-post-navigation__prev elementor-post-navigation__link\">\n\t\t\t\t<a href=\"https:\/\/www.jhm-biopharma.com\/en_US\/news\/p1314\/\" rel=\"prev\"><span class=\"elementor-post-navigation__link__prev\"><span class=\"post-navigation__prev--label\">Previous<\/span><span class=\"post-navigation__prev--title\">JHM Biopharmaceutical Begins Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke-Related Spasticity<\/span><\/span><\/a>\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-post-navigation__separator-wrapper\">\n\t\t\t\t\t<div class=\"elementor-post-navigation__separator\"><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"elementor-post-navigation__next elementor-post-navigation__link\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Today, JHM Biopharmaceutical (Hangzhou) Co., Ltd. (here&#8230;<\/p>\n","protected":false},"author":3,"featured_media":2261,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-2269","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.jhm-biopharma.com\/en_US\/wp-json\/wp\/v2\/posts\/2269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.jhm-biopharma.com\/en_US\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.jhm-biopharma.com\/en_US\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.jhm-biopharma.com\/en_US\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.jhm-biopharma.com\/en_US\/wp-json\/wp\/v2\/comments?post=2269"}],"version-history":[{"count":17,"href":"https:\/\/www.jhm-biopharma.com\/en_US\/wp-json\/wp\/v2\/posts\/2269\/revisions"}],"predecessor-version":[{"id":2315,"href":"https:\/\/www.jhm-biopharma.com\/en_US\/wp-json\/wp\/v2\/posts\/2269\/revisions\/2315"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.jhm-biopharma.com\/en_US\/wp-json\/wp\/v2\/media\/2261"}],"wp:attachment":[{"href":"https:\/\/www.jhm-biopharma.com\/en_US\/wp-json\/wp\/v2\/media?parent=2269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.jhm-biopharma.com\/en_US\/wp-json\/wp\/v2\/categories?post=2269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.jhm-biopharma.com\/en_US\/wp-json\/wp\/v2\/tags?post=2269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}